Corcept Therapeutics Inc. (CORT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.74 (-1.25%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Corcept Therapeutics Inc. (CORT)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Key Insights

Critical company metrics and information
  • Share Price

    $59.17
  • Market Cap

    $6.20 Billion
  • Total Outstanding Shares

    104.78 Million Shares
  • Total Employees

    352
  • Dividend

    No dividend
  • IPO Date

    April 14, 2004
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.corcept.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$-23.02 Million
Net Cash Flow From Operating Activities$144.65 Million
Net Cash Flow From Investing Activities$-96.15 Million
Net Cash Flow, Continuing$25.49 Million
Net Cash Flow From Operating Activities, Continuing$144.65 Million
Net Cash Flow$25.49 Million
Net Cash Flow From Investing Activities, Continuing$-96.15 Million
Net Cash Flow From Financing Activities, Continuing$-23.02 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Benefits Costs and Expenses$462.21 Million
Selling, General, and Administrative Expenses$244.10 Million
Basic Average Shares$308.91 Million
Preferred Stock Dividends And Other Adjustments$735,000.00
Basic Earnings Per Share$1.36
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$735,000.00
Net Income/Loss Available To Common Stockholders, Basic$140.47 Million
Diluted Earnings Per Share$1.26
Operating Expenses$475.39 Million
Costs And Expenses$485.20 Million
Revenues$628.55 Million
Net Income/Loss$141.82 Million
Income/Loss From Continuing Operations Before Tax$166.34 Million
Operating Income/Loss$143.36 Million
Cost Of Revenue$9.80 Million
Diluted Average Shares$334.57 Million
Gross Profit$618.75 Million
Research and Development$231.29 Million
Nonoperating Income/Loss$22.98 Million
Income Tax Expense/Benefit, Deferred$-40.01 Million
Income Tax Expense/Benefit$24.52 Million
Net Income/Loss Attributable To Parent$141.82 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$141.82 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0.00
Other Current Assets$453.11 Million
Inventory$8.05 Million
Noncurrent Liabilities$19.21 Million
Noncurrent Assets$317.28 Million
Equity Attributable To Parent$638.84 Million
Current Assets$466.98 Million
Fixed Assets$2.93 Million
Liabilities$145.42 Million
Other Non-current Assets$314.35 Million
Other Current Liabilities$107.63 Million
Current Liabilities$126.22 Million
Accounts Payable$18.58 Million
Prepaid Expenses$5.82 Million
Liabilities And Equity$784.26 Million
Assets$784.26 Million
Equity$638.84 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.